Six minute walking test and carbon monoxide diffusing capacity for non-small cell lung cancer: Easy performed tests in every day practice

Journal of Thoracic Disease

Volumn 4, Issue 6, 2012, Pages 569-576

  Zarogoulidis, Paul ^a   Kerenidi, Theodora ^b   Huang, Haidong ^c   Kontakiotis, Theodoras ^a   Tremma, Ourania ^a   Porpodis, Konstantinos ^a   Kalianos, Anastasios ^d   Rapti, Ageliki ^d   Foroulis, Christoforos ^e   Zissimopoulos, Athanasios ^f   Courcoutsakis, Nikolaos ^f   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d Hospital of Chest Diseases Sotiria   (Greece)

^e AHEPA UNIVERSITY HOSPITAL   (Greece)

^f UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

Author keywords

6MWT; DLCO; FEV1; FVC; NSCLC

Indexed keywords

CARBON MONOXIDE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CARBON MONOXIDE DIFFUSING CAPACITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG BILOBECTOMY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SIX MINUTE WALKING TEST; TASK PERFORMANCE; WALKING;

EID: 84873670658     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.08.18     Document Type: Article

References (45)

1. Jemal A, Bray F, Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Petty TL. Are COPD and lung cancer two manifestations of the same disease? Chest 2005; 128: 1895-7.
3. Nomura A, Stemmermann GN, Chyou P.H., et al. Prospective study of pulmonary function and lung cancer. Am Rev Respir Dis 1991; 144: 307-11.
4. Calabrò E, Randi G, La Vecchia C, et al. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur Respir J 2010; 35: 146-51.
5. Reif MS, Socinski MA, Rivera MP Evidence-based medicine in the treatment of non-small-cell lung cancer. Clin Chest Med 2000; 21: 107-20, he.
6. Win T, Jackson A, Sharpies L., et al. Relationship between pulmonary function and lung cancer surgical outcome. Eur Respir J 2005; 25: 594-9.
7. Birim O, Kappetein AP, van Klaveren RJ, et al. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 2006; 32: 12-23.
8. Colice GL, Shafazand S, Griffin J.P., et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:161S-77S.
9. Lim E, Baldwin D, Beckles M., et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010; 65: iii1-27.
10. Brunelli A, Charloux A, Bolliger C.T., et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemoradiotherapy). Eur Respir J 2009; 34: 17-41.
11. Liptay MJ, Basu S, Hoaglin M.C., et al. Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. J Surg Oncol 2009; 100: 703-7.
12. Licker M, Schnyder JM, Frey J.G., et al. Impact of aerobic exercise capacity and procedure-related factors in lung cancer surgery. Eur Respir J 2011; 37: 1189-98.
13. Brundage MD, Davies D, Mackillop WJ Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122: 1037-57.
14. Waller D, Peake MD, Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26: 173-82.
15. Albain KS, Crowley JJ, Le Blanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-26.
16. Zarogoulidis K, Kontakiotis T, Hatziapostolou P., et al. A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer 2001; 32: 281-7.
17. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994; 344: 1267-72.
18. De Petris L., Crinó L, Scagliotti GV, et al. Treatment of advanced non-small cell lung cancer. Ann Oncol 2006; 17: ii36-41.
19. Kubota K, Kawahara M, Ogawara M., et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008; 9: 1135-42.
20. Greene FL, Sobin LH The TNM system: our language for cancer care. J Surg Oncol 2002; 80: 119-20.
21. Miller MR, Hankinson J, Brusasco V., et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
22. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 2002; 166: 111-7.
23. Arriagada R, Bergman B, Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60.
24. Barnett SA, Rusch VW, Zheng J, et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol 2011; 6: 1530-6.
25. Basaki K, Abe Y, Aoki M., et al. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 2006; 64: 449-54.
26. Jeremic B, Milicic B, Milisavljevic S. Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients. Cancer 2011; 117: 2995-3003.
27. Lee JH, Song EM, Sim Y.S., et al. Forced expiratory volume in one second as a prognostic factor in advanced non-small cell lung cancer. J Thorac Oncol 2011; 6: 305-9.
28. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-5; discussion 715-6
29. Koh WP, Yuan JM, Wang R, et al. Body mass index and smoking-related lung cancer risk in the Singapore Chinese Health Study. Br J Cancer 2010; 102: 610-4.
30. Pauwels RA, Buist AS, Calverley P.M., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163: 1256-76.
31. Win T, Groves AM, Ritchie A.J., et al. The effect of lung resection on pulmonary function and exercise capacity in lung cancer patients. Respir Care 2007; 52: 720-6.
32. Borst GR, De Jaeger K, Belderbos JS, et al. Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys 2005; 62: 639-44.
33. Sarna L, Evangelista L, Tashkin D., et al. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest 2004; 125: 439-45.
34. Jones LW, Eves ND, Kraus W.E., et al. The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. BMC Cancer 2010, 10:155.
35. Haugnes HS, Aass N, Fossa S.D., et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27: 2779-86.
36. Kasymjanova G, Correa JA, Kreisman H, et al. Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 602-7.
37. Pinto-Plata V.M., Cote C, Cabrai H., et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28-33.
38. Jay SJ. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 2000; 161:1396.
39. Glattki GP, Manika K, Sichletidis L., et al. Pulmonary rehabilitation in non-small cell lung cancer patients after completion of treatment. Am J Clin Oncol 2012; 35: 120-5.
40. Ferguson MK, Reeder LB, Mick R. Optimizing selection of patients for major lung resection. J Thorac Cardiovasc Surg 1995; 109: 275-81; discussion 281-3
41. Nishimura H, Haniuda M, Morimoto M., et al. Cardiopulmonary function after pulmonary lobectomy in patients with lung cancer. Ann Thorac Surg 1993; 55: 1477-84.
42. Semrau S, Klautke G, Fietkau R. Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases. Int J Radiat Oncol Biol Phys 2011; 79: 96-104.
43. Bolliger CT, Perruchoud AP Functional evaluation of the lung resection candidate. Eur Respir J 1998; 11: 198-212.
44. Camus P. Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer 2004; 91: 51-2.
45. Camus P, Fanton A, Bonniaud P., et al. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71: 301-26.